Endothelial Cell News Volume 1.00 | Mar 7 2016

The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis
Researchers generated a mouse expressing additional copies of the tRNA_i^Met gene (2+tRNA_i^Met mouse). Growth and vascularization of subcutaneous tumor allografts was enhanced in 2+tRNA_i^Met mice compared with wild-type littermate controls. Extracellular matrix deposited by fibroblasts from 2+tRNA_i^Met mice supported enhanced endothelial cell and fibroblast migration. [Curr Biol] Abstract | Press Release

Endothelial Cell Survival during Angiogenesis Requires the Pro-Survival Protein MCL1
Scientists investigated the in vivo role of myeloid cell leukemia 1 (MCL1), a pro-survival member of the BCL2 family, in endothelial cell (EC) survival during angiogenesis. EC-specific deletion of Mcl1 resulted in a dose-dependent increase in EC apoptosis in the angiogenic vasculature and a corresponding decline in vessel density. [Cell Death Differ] Abstract

Endothelial Cells Decode VEGF-Mediated Ca²⁺ Signaling Patterns to Produce Distinct Functional Responses
Researchers found that VEGF triggers proliferation or migration in endothelial cells by stimulating different calcium signaling patterns. [Sci Signal] Abstract

Three-Dimensional Characterization of Mechanical Interactions between Endothelial Cells and Extracellular Matrix during Angiogenic Sprouting
Researchers studied the three-dimensional cell-extracellular matrix interactions of endothelial cells that form multicellular structures called sprouts. They analyzed data collected in-situ from angiogenic sprouting experiments and identified the differentiated interaction behavior exhibited by the tip and stalk cells. [Sci Rep] Full Article

Tumor-Induced Remote ECM Network Orientation Steers Angiogenesis
Investigators use automated sequential microprinting of tumor and endothelial cells in extracellular matrix (ECM) scaffolds to study its mechanical aspects. Quantitative reflection microscopy shows that tumor spheroids induce radial orientation of the surrounding collagen fiber network up to a distance of five times their radius. [Sci Rep] Full Article

Advanced Age Decreases Local Calcium Signaling in Endothelium of Mouse Mesenteric Arteries In Vivo
Scientists tested the hypothesis that local endothelial cell Ca²⁺ signaling is impaired with advanced age along with a reduction in internal elastic lamina holes. [Am J Physiol Heart Circ Physiol] Abstract

Inhibition of Development of Laser-Induced Choroidal Neovascularization with Suppression of Infiltration of Macrophages in Smad3-Null Mice
The authors evaluated the effects of the loss of Smad3 on the development of experimental argon laser-induced choroidal neovascularization in mice. An in vitro angiogenesis model was also used to examine the role of transforming growth factor-β1/Smad3 signaling in vessel-like tube formation by human umbilical vein endothelial cells. [Lab Invest] Abstract

Abnormal Correlation of Circulating Endothelial Progenitor Cells and Endothelin-1 Concentration May Contribute to the Development of Arterial Hypertension in Childhood Acute Lymphoblastic Leukemia Survivors
Investigators determined the relationship between the rate of circulating endothelial progenitor cells and plasma levels of endothelin-1 with respect to hypertension in childhood acute lymphoblastic leukemia survivors. [Hypertens Res] Abstract

Visit our reviews page to see a complete list of reviews in the endothelial cell research field.

Chi-Med Initiates Sulfatinib Phase II Clinical Trial in Thyroid Cancer
Hutchison China MediTech Limited announced that Hutchison MediPharma Limited has initiated an open-label Phase II clinical trial to evaluate the efficacy and safety of sulfatinib in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer in China [Hutchison China MediTech Limite] Press Release

Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan
Exelixis, Inc. and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside of the United States, Canada and Japan. [Exelixis, Inc.] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the endothelial cell community.

Senior Research Fellow – Cancer Biology/Immunology (Plymouth University)

Postdoctoral Position – Cardiovascular Basic and Translational Research (University Clinic Heidelberg)

PhD Student Position – Cardiovascular Basic and Translational Research (University Clinic Heidelberg)

Postdoctoral Research Scientist – Wound Healing and Inflammation (Inserm)

Research Asst Professor/Postdoctoral Fellow Positions – Vascular Biology (University of Illinois)

Postdoctoral Position – Modeling and Analysis of Receptor Interactions (UT Southwestern Medical Center)

Postdoctoral Fellow – Molecular Mechanisms of Angiogenesis and Atherosclerosis (The University of Tennessee Health Science Center)

Postdoctoral Scientist – Isoprenoid Metabolism in Angiogenesis and Cancer (VIB)

PhD Positions – Metabolism and Cancer (VIB)

Postdoctoral Fellow/Research Associate – Translational Genomics and Cancer Immunobiology & Immunotherapy (Children’s Hospital of Philadelphia)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.